百花医药最新公告：拟使用19.10亿元资本公积金弥补亏损

Core Points - The company, Baihua Pharmaceutical (600721.SH), announced that it will hold a board and shareholder meeting on October 27, 2025, to approve the use of a total of 1.91 billion yuan from the parent company's surplus reserve and capital reserve to cover losses [1] - The negative retained earnings of the parent company are primarily due to goodwill impairment from a previous major asset restructuring, which has impacted the company's asset impairment [1] - The company has notified creditors that they can request debt repayment or corresponding guarantees within 30 days of receiving the notice or within 45 days from the date of the announcement [1]